- Home
- ZYME vs IRS Comparison
ZYME vs IRS Comparison
Compare ZYME & IRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZYME
- IRS
- Stock Information
- Founded
- ZYME 2003
- IRS 1943
- Country
- ZYME United States
- IRS Argentina
- Employees
- ZYME N/A
- IRS N/A
- Industry
- ZYME Biotechnology: Pharmaceutical Preparations
- IRS Homebuilding
- Sector
- ZYME Health Care
- IRS Real Estate
- Exchange
- ZYME Nasdaq
- IRS Nasdaq
- Market Cap
- ZYME 968.5M
- IRS 1.1B
- IPO Year
- ZYME 2017
- IRS 1994
- Fundamental
- Price
- ZYME $12.43
- IRS $16.10
- Analyst Decision
- ZYME Buy
- IRS Strong Buy
- Analyst Count
- ZYME 7
- IRS 1
- Target Price
- ZYME $19.50
- IRS $12.62
- AVG Volume (30 Days)
- ZYME 409.0K
- IRS 170.1K
- Earning Date
- ZYME 08-07-2025
- IRS 09-02-2025
- Dividend Yield
- ZYME N/A
- IRS 6.22%
- EPS Growth
- ZYME N/A
- IRS N/A
- EPS
- ZYME N/A
- IRS 0.20
- Revenue
- ZYME $93,384,000.00
- IRS $308,539,877.00
- Revenue This Year
- ZYME $44.71
- IRS N/A
- Revenue Next Year
- ZYME $34.57
- IRS N/A
- P/E Ratio
- ZYME N/A
- IRS $7.22
- Revenue Growth
- ZYME 85.05
- IRS N/A
- 52 Week Low
- ZYME $9.03
- IRS $8.49
- 52 Week High
- ZYME $17.70
- IRS $17.67
- Technical
- Relative Strength Index (RSI)
- ZYME 40.44
- IRS 62.25
- Support Level
- ZYME $12.26
- IRS $14.52
- Resistance Level
- ZYME $13.80
- IRS $16.43
- Average True Range (ATR)
- ZYME 0.62
- IRS 0.64
- MACD
- ZYME -0.21
- IRS 0.05
- Stochastic Oscillator
- ZYME 10.19
- IRS 84.35
About ZYME Zymeworks Inc.
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.
About IRS IRSA Inversiones Y Representaciones S.A. Global Depositary Shares (Each representing ten shares of)
IRSA Inversiones y Representaciones SA is engaged in a diversified business. The company's operating segment includes Shopping Malls; Offices; Sales and Developments; Hotels and others. It generates maximum revenue from the Shopping Malls segment. The Shopping Malls segment comprised of lease and service revenues related to rental of commercial space and other spaces in the shopping malls of the company.